Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator
Abha Saxena
(1)
,
Brook Baker
(2)
,
Amanda Banda
(3)
,
Anders Herlitz
(4, 5)
,
Jennifer Miller
(6)
,
Karrar Karrar
(7)
,
Marc Fleurbaey
(8, 9)
,
Esther Chiwa
(10)
,
Caesar Alimisnya Atuire
(11)
,
Iwao Hirose
(12)
,
Nicole Hassoun
(13)
1
Independent Bioethics Advisor
2 Northeastern University School of Law
3 Wemos
4 University of Gothenburg
5 The Institute for Futures Studies, Stockholm
6 YSM - Yale School of Medicine [New Haven, Connecticut]
7 Save the Children-UK
8 PSE - Paris School of Economics
9 ENS-PSL - École normale supérieure - Paris
10 Malawi Ministry of Health
11 University of Ghana
12 McGill University = Université McGill [Montréal, Canada]
13 Binghamton University [SUNY]
2 Northeastern University School of Law
3 Wemos
4 University of Gothenburg
5 The Institute for Futures Studies, Stockholm
6 YSM - Yale School of Medicine [New Haven, Connecticut]
7 Save the Children-UK
8 PSE - Paris School of Economics
9 ENS-PSL - École normale supérieure - Paris
10 Malawi Ministry of Health
11 University of Ghana
12 McGill University = Université McGill [Montréal, Canada]
13 Binghamton University [SUNY]
Abha Saxena
- Fonction : Auteur
- PersonId : 1332617
- ORCID : 0000-0002-9423-120X
Marc Fleurbaey
- Fonction : Auteur
- PersonId : 741339
- IdHAL : marc-fleurbaey
- ORCID : 0000-0002-5342-8065
- IdRef : 029286719
Caesar Alimisnya Atuire
- Fonction : Auteur
- PersonId : 1332618
- ORCID : 0000-0001-6825-6916
Nicole Hassoun
- Fonction : Auteur
- PersonId : 1332619
- ORCID : 0000-0002-5547-1710
Résumé
Nationalism has trumped solidarity, resulting in unnecessary loss of life and inequitable access to vaccines and therapeutics. Existing intellectual property (IP) regimens, trade secrets and data rights, under which pharmaceutical firms operate, have also posed obstacles to increasing manufacturing capacity, and ensuring adequate supply, affordable pricing, and equitable access to COVID-19 vaccines and other health products in low-income and middle- income countries. We propose: (1) Implementing alternative incentive and funding mechanisms to develop new scientific innovations to address infectious diseases with pandemic potential; (2) Voluntary and involuntary initiatives to overcome IP barriers including pooling IP, sharing data and vesting licences for resulting products in a globally agreed entity; (3) Transparent and accountable collective procurement to enable equitable distribution; (4) Investments in regionally distributed research and development (R&D) capacity and manufacturing, basic health systems to expand equitable access to essential health technologies, and non-discriminatory national distribution; (5) Commitment to strengthen national (and regional) initiatives in the areas of health system development, health research, drug and vaccine manufacturing and regulatory oversight and (6) Good governance of the pandemic prevention, preparedness and response accord. It is important to articulate principles for deals that include reasonable access conditions and transparency in negotiations. We argue for an equitable, transparent, accountable new global agreement to provide rewards for R&D but only on the condition that pharmaceutical companies share the IP rights necessary to produce and distribute them globally. Moreover, if countries commit to collective procurement and fair pricing of resulting products, we argue that we can greatly improve our ability to prepare for and respond to pandemic threats.
Domaines
Economies et financesFormat du dépôt | Notice |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator
|
Résumé |
en
Nationalism has trumped solidarity, resulting in unnecessary loss of life and inequitable access to vaccines and therapeutics. Existing intellectual property (IP) regimens, trade secrets and data rights, under which pharmaceutical firms operate, have also posed obstacles to increasing manufacturing capacity, and ensuring adequate supply, affordable pricing, and equitable access to COVID-19 vaccines and other health products in low-income and middle- income countries. We propose: (1) Implementing alternative incentive and funding mechanisms to develop new scientific innovations to address infectious diseases with pandemic potential; (2) Voluntary and involuntary initiatives to overcome IP barriers including pooling IP, sharing data and vesting licences for resulting products in a globally agreed entity; (3) Transparent and accountable collective procurement to enable equitable distribution; (4) Investments in regionally distributed research and development (R&D) capacity and manufacturing, basic health systems to expand equitable access to essential health technologies, and non-discriminatory national distribution; (5) Commitment to strengthen national (and regional) initiatives in the areas of health system development, health research, drug and vaccine manufacturing and regulatory oversight and (6) Good governance of the pandemic prevention, preparedness and response accord. It is important to articulate principles for deals that include reasonable access conditions and transparency in negotiations. We argue for an equitable, transparent, accountable new global agreement to provide rewards for R&D but only on the condition that pharmaceutical companies share the IP rights necessary to produce and distribute them globally. Moreover, if countries commit to collective procurement and fair pricing of resulting products, we argue that we can greatly improve our ability to prepare for and respond to pandemic threats.
|
Auteur(s) |
Abha Saxena
1
, Brook Baker
2
, Amanda Banda
3
, Anders Herlitz
4, 5
, Jennifer Miller
6
, Karrar Karrar
7
, Marc Fleurbaey
8, 9
, Esther Chiwa
10
, Caesar Alimisnya Atuire
11
, Iwao Hirose
12
, Nicole Hassoun
13
1
Independent Bioethics Advisor
( 1184876 )
- Suisse
2
Northeastern University School of Law
( 1184877 )
- États-Unis
3
Wemos
( 1184878 )
- Pays-Bas
4
University of Gothenburg
( 1184879 )
- Suède
5
The Institute for Futures Studies, Stockholm
( 1080252 )
- The Institute for Futures Studies, Stockholm 111 36, Sweden
- Suède
6
YSM -
Yale School of Medicine [New Haven, Connecticut]
( 51214 )
- Yale University School of Medicine - 333 Cedar Street - New Haven, CT 06510
- États-Unis
7
Save the Children-UK
( 352513 )
-
- France
8
PSE -
Paris School of Economics
( 301309 )
- 48 boulevard Jourdan 75014 Paris
- France
9
ENS-PSL -
École normale supérieure - Paris
( 59704 )
- 45, Rue d'Ulm - 75230 Paris cedex 05
- France
10
Malawi Ministry of Health
( 1184880 )
- Malawi
11
University of Ghana
( 230533 )
- P.O. Box LG 25
Legon, Accra
- Ghana
12
McGill University = Université McGill [Montréal, Canada]
( 134741 )
- 845, rue Sherbrooke O. Montréal (Québec) Canada H3A 0G4
- Canada
13
Binghamton University [SUNY]
( 325206 )
- Binghamton University
State University of New York
4400 Vestal Parkway East
Binghamton, NY 13902
- États-Unis
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Langue du document |
Anglais
|
Nom de la revue |
|
Date de publication |
2023-01
|
Volume |
8
|
Numéro |
1
|
Domaine(s) |
|
DOI | 10.1136/bmjgh-2022-010615 |
Loading...